メタロチオネインプロモーター制御下でがん遺伝子RETならびにDct陽性細胞 (メラノサイト) でlacZが発現するトランスジェニックマウス。皮膚黒色症モデル。腫瘍は発症しない。RET Tgホモは致死。 B6.Cg-Tg(Mt1-RET)242Ina Tg(Dct-LacZ)A12Jkn B6.Cg-Tg(Mt1-RET)242Ina Tg(Dct-LacZ)A12Jkn 242RET;Dct-LacZ 242RET;Dct-LacZ Mt1-RET/Dct-lacZ Tg mice. These mice express the lacZ in melanocytes under the control of Dct promoter and the human RET under the control of the mouse MT1 promoter/enhancer. Mt1-RET homozygous mutant mice are embryonic lethal. Mouse Models for Human Disease Developed by Masashi Kato, Nagoya University Graduate School of Medicine. Generated by crossing of RET mice and Hr mice (Hos:HRM). The mice were backcrossed to C57BL/6 over 10 times. C (3-6 months) Dermatology Research 名古屋大学大学院医学系研究科・加藤昌志。RETマウスTg(Mt1-RET)242InaとHos:HRMマウスとの交配より作出。C57BL/6へ戻し交配された（N10以上）。 C（3〜6か月） true <a href='https://brc.riken.jp/mus/pcr05943'>Genotyping protocol -PCR-</a> Masashi KATO 条件を付加する。利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。<br>営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 RBRC05943 Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> Mt1-RET: Carrier x Noncarrier; Dct-lacZ: Carrier x Carrier (Homozygote x Homozygote) Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Mt1-RET: Carrier x Noncarrier; Dct-lacZ: Carrier x Carrier (Homozygote x Homozygote) 加藤　昌志 Cancer Research Fluorescent Proteins/lacZ System Mus musclus Metallothionein-I promoter-enhancer, Homo sapiens RFP/RET cDNA, SV40 splicing signal-polyadenylation site, vector sequence, Mus musuculus Dct promoter, Escherichia coli LacZ